Table 1 -Medical treatments administered to patients associated with treatment of GBM or historical diagnoses. Medication All dogs # (%) Sx # (%) Med # (%) Med-Sx # (%) Ursodeoxycholic acid (UDCA) 61 (68.5) 22 (47.8) 30 (90.9) 9 (90) Opioid 45 (50.6) 35 (76.1) 6 (18.2) 4 (40)
Ampicillin 7 (7.9) 2 (4.4) 0 (0) 5 (50) Amoxicillin 7 (7.9) 2 (4.4) 3 (9.1) 2 (20)
Vitamin E 7 (7.9) 1 (2.2) 4 (12.1) 2 (20)
Ampicillin Sulbactam 6 (6.7) 6 (13.0) 0 (0) 0 (0) N-acetylcysteine 6 (6.7) 5 (10.8) 1 (3.0) 0 (0) Trilostane 6 (6.7) 1 (2.2) 4 (12.1) 1 (10) Insulin 6 (6.7) 1 (2.2) 4 (9.1) 2 (20)
Amlodipine 5 (5.6) 3 (6.5) 1 (3.0) 0 (0) Phenobarbital 4 (4.5) 3 (6.5) 1 (3.0) 0 (0) Mirtazapine 4 (4.5) 2 (4.4) 2 (6.1) 0 (0) NSAID (systemic) 4 (4.5) 3 (6.5) 1 (3.0) 0 (0) Vitamin K 4 (4.5) 4 (8.7) 0 (0) 0 (0)
Medication

All dogs # (%) Sx # (%) Med # (%) Med-Sx # (%)
Cyclosporine (ophthalmic) 3 (3.4) 1 (2.2) 2 (6.1) 0 (0) Omega-3 fatty acid 3 (3.4) 0 (0) 3 (9.1) 0 (0) Cobalamine 1 (1.1) 0 (0) 0 (0) 1 (10)
Sx, surgical treatment group; Med, medically managed group; Med-Sx, medical then surgical group;
ACEi, angiotensin converting enzyme inhibitor; NSAID, non-steroidal anti-inflammatory drug.
Number of dogs receiving a medication reported as #, total number within treatment group; and (%), percent within treatment group.
